They actually had a table on the efficacy for severe cases in the supplemental material of the original Pfizer study (table S5 in [1]), but all it shows is that

They actually had a table on the efficacy for severe cases in the supplemental material of the original Pfizer study (table S5 in [1]), but all it shows is that the study doesn’t really give any information on this. The 95% confidence interval given for severe cases after the first vaccine is 20.1–99.7%. From what I understand, it’s really a trade-off between waiting for proper data about the efficacy you’re most interested in, or starting to vaccinate people as soon as you have efficacy data for an endpoint that’s still meaningful but easier to reach. Having much fewer symptomatic cases is already a pretty good result, and I think it was expected that the protection would also extend to severe cases. [1]: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2034577/suppl_file/nejmoa2034577_appendix.pdf https://www.nejm.org/doi/suppl/10.1056/NEJMoa2034577/suppl_f...